Search by Drug Name or NDC
NDC 50474-0470-14 Briviact 25 mg/1 Details
Briviact 25 mg/1
Briviact is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by UCB, Inc.. The primary component is BRIVARACETAM.
MedlinePlus Drug Summary
Brivaracetam is used alone and in combination with other medications to control partial onset seizures (seizures that involve only one part of the brain) in adults, children, and infants 1 month of age and older. Brivaracetam is in a class of medications called anticonvulsants. It works by decreasing abnormal electrical activity in the brain.
Related Packages: 50474-0470-14Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Brivaracetam
Product Information
| NDC | 50474-0470 |
|---|---|
| Product ID | 50474-470_c6efa4e8-aa1f-4436-b0a7-2ccffb971275 |
| Associated GPIs | 72600015000320 |
| GCN Sequence Number | 075599 |
| GCN Sequence Number Description | brivaracetam TABLET 25 MG ORAL |
| HIC3 | H4B |
| HIC3 Description | ANTICONVULSANTS |
| GCN | 40717 |
| HICL Sequence Number | 043088 |
| HICL Sequence Number Description | BRIVARACETAM |
| Brand/Generic | Brand |
| Proprietary Name | Briviact |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | brivaracetam |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, FILM COATED |
| Route | ORAL |
| Active Ingredient Strength | 25 |
| Active Ingredient Units | mg/1 |
| Substance Name | BRIVARACETAM |
| Labeler Name | UCB, Inc. |
| Pharmaceutical Class | Epoxide Hydrolase Inhibitors [MoA] |
| DEA Schedule | CV |
| Marketing Category | NDA |
| Application Number | NDA205836 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 50474-0470-14 (50474047014)
| NDC Package Code | 50474-470-14 |
|---|---|
| Billing NDC | 50474047014 |
| Package | 1 BLISTER PACK in 1 CARTON (50474-470-14) / 14 TABLET, FILM COATED in 1 BLISTER PACK |
| Marketing Start Date | 2016-05-12 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |